Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2017) 48 P1 | DOI: 10.1530/endoabs.48.P1

SFEEU2017 Obesity Update Poster Presentations (14 abstracts)

Weight loss and associated improvements in cardiometabolic risk factors with liraglutide 3.0 mg in the SCALE Obesity and Prediabetes randomised, double-blind, placebo-controlled 3-year trial

Barbara McGowan 1 , Ken Fujioka 2 , Frank Greenway 3 , Michel Krempf 4 , Carel Le Roux 5 , Roberto Vettor 6 , Soren Lilleore 7 & Arne Astrup 8


1Guy’s and St Thomas’ NHS Foundation Trust, London, UK; 2Scripps Clinic, La Jolla, CA, USA; 3Pennington Biomedical Research Center, Baton Rouge, LA, USA; 4Université de Nantes, Nantes, France; 5University College Dublin, Dublin, Ireland; 6University of Padua, Padua, Italy; 7Novo Nordisk, Soeborg, Denmark; 8University of Copenhagen, Frederiksberg, Denmark.


Aims/objectives: Obesity and prediabetes are risk factors for developing T2D. 5–10% weight-loss can reduce risk of developing T2D by >50%. The 3-year part of this phase 3 trial investigated effects of liraglutide 3.0 mg, as adjunct to diet+exercise, in delaying onset of T2D over 3 years, body-weight and cardiometabolic risk factors in adults with obesity or overweight with comorbidities, and diagnosed with prediabetes at screening.

Methods: Individuals (BMI ≥30 kg/m2, or ≥27 kg/m2 with ≥1 comorbidity) were randomised 2:1 to once-daily subcutaneous liraglutide 3.0 mg (n=1505) or placebo (n=749) and advised on a 500-kcal/day deficit diet and 150-min/week exercise. Efficacy data are observed means, with last-observation-carried-forward (LOCF) imputation. (NCT01272219).

Results: Baseline characteristics were (mean±S.D.): age 47.5±11.7 years, 76.0% female, weight 107.6±21.6 kg, BMI 38.8±6.4 kg/m2. With continued treatment over 160 weeks, estimated time to onset of diabetes was 2.7 times longer with liraglutide 3.0 mg than with placebo (95% CI, 1.9–3.9, P<0.001), corresponding to a HR of 0.2. Based on the Kaplan-Meier plot of cumulative probability of a diagnosis of diabetes, 3% of patients in the liraglutide group vs 11% in the placebo group were diagnosed with diabetes by week 160 while on treatment. More individuals on liraglutide (66%) vs placebo (36%) regressed to normoglycaemia by week 160 (OR 3.6 [3.0;4.4], P<0.001). Individuals on liraglutide 3.0 mg lost more weight than on placebo (6.1% vs 1.9%; ETD −4.3% [95%CI −4.9;−3.7]), accompanied by greater mean reductions in waist circumference (ETD −3.5 [−4.2;−2.8] cm), SBP (ETD −2.8 [−3.8;−1.8] mmHg), triglycerides (ETD −6%[−9;−3]) and high-sensitivity C-reactive protein (ETD 29% [−34;−23]) (all P<0.001). Mean pulse increased with liraglutide 3.0 mg vs placebo (ETD 2.0 [1.2;2.7] beats/min, P<0.0001). AE incidence was 94.7% with liraglutide 3.0 mg vs 89.4% with placebo, SAEs 15.1% vs 12.9%. Adjudicated major adverse CV events (non-fatal MI, stroke, cardiovascular death) were low overall (0.19 vs 0.20 events/100 patient-years-of-observation for liraglutide 3.0 mg vs placebo).

Conclusion: Liraglutide 3.0 mg for 3 years, as an adjunct to diet+exercise, was associated with lower risk of T2D and greater weight loss, and improved cardiometabolic risk factors compared with placebo.

Volume 48

Society for Endocrinology Endocrine Update 2017

Society for Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.